Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia

Innate Immunity

Volumn 14, Issue 5, 2008, Pages 269-278

  Chen, Wilbur H ^a   Kang, Tae Jin ^a,c   Bhattacharjee, Apurba K ^b   Cross, Alan S ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Sahmyook University   (South Korea)

Author keywords

Endotoxin; Mucosal immunity; Pneumonia; Sepsis; Vaccine

Indexed keywords

BACTERIAL VACCINE; CPG OLIGODEOXYNUCLEOTIDE; ENDOTOXIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; FEMALE; GRAM NEGATIVE BACTERIUM; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; INJECTIONS, INTRAPERITONEAL; LIPOPOLYSACCHARIDES; MICE; PNEUMONIA, BACTERIAL; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, CONJUGATE;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; NEGIBACTERIA;

EID: 61349117483     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908095959     Document Type: Article

References (38)

1. Perl TM, Dvorak L., Hwang T., Wenzel RP Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995; 274: 338-345.
2. Baughman RP, Tapson V., McIvor A. The diagnosis and treatment challenges in nosocomial pneumonia. Diagn Microbiol Infect Dis 1999; 33: 131-139.
3. Jones RN Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 2001; 119: 397S-404S.
4. Cryz Jr SJ, Lang AB, Sadoff JC, Germanier R., Furer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun 1987; 55: 1547-1551.
5. Cryz Jr SJ, Cross AS, Sadoff JC, Furer E. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines. Infect Immun 1990; 58: 373-377.
6. Trautmann M., Held TK, Cross AS O antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Vaccine 2004; 22: 818-821.
7. Elbein AD, Heath EC The biosynthesis of cell wall lipopolysaccharide in Escherichia coli: The biochemical properties of a uridine diphosphate galactose 4-epimeraseless mutant. J Biol Chem 1965; 240: 1919-1925.
8. Ziegler EJ, Douglas H., Sherman JE, Davis CE, Braude AI Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol 1973; 111: 433-438.
9. Ziegler EJ, McCutchan JA, Douglas H., Braude AI Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Trans Assoc Am Phys 1975; 88: 101-108.
10. Ziegler EJ, McCutchan JA, Fierer J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-1230.
11. Bhattacharjee AK, Opal SM, Taylor R. et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. J Infect Dis 1996; 173: 1157-1163.
12. Cross AS, Opal SM, Warren HS et al. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183: 1079-1086.
13. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002; 32: 179-185.
14. Trautmann M., Vogt K., Hammack C., Cross AS A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides. Infect Immun 1994; 62: 1282-1288.
15. Bhattacharjee AK, Opal SM, Palardy JE et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against Gram-negative bacterial sepsis. J Infect Dis 1994; 170: 622-629.
16. Kang TJ, Fenton MJ, Weiner MA et al. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 2005; 73: 7495-7501.
17. Lu W., Hisatsune A., Koga T. et al. Enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J Immunol 2006; 176: 3890-3894.
18. Opal SM, Palardy JE, Chen WH, Parejo NA, Bhattacharjee AK, Cross AS Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: Its use with CpG adjuvant and potential mechanisms. J Infect Dis 2005; 192: 2074-2080.
19. Hirano T., Hou Y., Jiao X., Gu XX Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 2003; 35: 1-10.
20. Jiao X., Hirano T., Hou Y., Gu XX Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 2002; 70: 5982-5989.
21. Bhattacharjee AK, Van de Verg L., Izadjoo MJ et al. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect Immun 2002; 70: 3324-3329.
22. Van de Verg L., Hartman AB, Bhattacharjee AK et al. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Infect Immun 1996; 64: 5263-5268.
23. Orr N., Robin G., Cohen D., Arnon R., Lowell GH Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 1993; 61: 2390-2395.
24. DiGiandomenico A., Rao J., Harcher K. et al. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2007; 104: 4624-4629.
25. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25: 5467-5484.
26. Snoeck V., Peters IR, Cox E. The IgA system: A comparison of structure and function in different species. Vet Res 2006; 37: 455-467.
27. Renegar KB, Small Jr PA, Boykins LG, Wright PF Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173: 1978-1986.
28. Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61: 2741-2747.
29. McCluskie MJ, Davis HL CpG DNA as mucosal adjuvant. Vaccine 1999; 18: 231-237.
30. Wongratanacheewin S., Kespichayawattana W., Intachote P. et al. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun 2004; 72: 4494-4502.
31. Elkins KL, Rhinehart-Jones TR, Stibitz S., Conover JS, Klinman DM Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162: 2291-2298.
32. Klinman DM, Conover J., Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 1999; 67: 5658-5663.
33. Deng JC, Moore TA, Newstead MW, Zeng X., Krieg AM, Standiford TJ CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol 2004; 173: 5148-5155.
34. Nichani AK, Dar MA, Krieg AM et al. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. Vet Immunol Immunopathol 2007; 115: 357-368.
35. LaForce FM, Boose DS, Mills DM Heightened lung bactericidal activity in mice after aerosol immunization with Re 595 Salmonella minnesota: importance of cellular rather than humoral factors. J Infect Dis 1980; 142: 421-431.
36. Robbins JB, Schneerson R., Szu SC Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171: 1387-1398.
37. Robbins JB, Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1992; 15: 346-361.
38. Martin TR, Frevert CW Innate immunity in the lungs. Proc Am Thorac Soc 2005; 2: 403-411.